China's Q2 GDP grows 5.2% y/y, above market forecast
Analysts polled by Reuters had forecast second-quarter gross domestic product (GDP) would expand 5.1% from a year earlier, slowing from the first-quarter's 5.4% pace.
China has set a full-year growth target of around 5%.
On a quarterly basis, GDP grew 1.1% in April-June, the National Bureau of Statistics data showed, compared with a forecast 0.9% increase and a 1.2% gain in the previous quarter.
The world's second-largest economy has so far avoided a sharp slowdown in part due to policy support and a fragile U.S.-China trade truce, but markets are braced for weaker growth in the second half pressured by slowing exports, low consumer confidence and a persistent property downturn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Russian rouble, stock market gain after Trump's statement on Russia
MOSCOW (Reuters) -The Russian rouble reversed losses against the dollar and rose against China's yuan after U.S. President Donald Trump warned he would impose "very severe tariffs" on Russia if no deal on a peaceful settlement is made in 50 days. As of 1605 GMT, the rouble was 0.2% weaker at 78.10 per U.S. dollar after hitting 78.75 during the day, according to LSEG data based on over-the-counter quotes. The rouble is up about 45% against the dollar since the start of the year. Trump announced new weapons for Ukraine on Monday and threatened to hit buyers of Russian exports with sanctions, expressing frustration with Russian President Vladimir Putin due to the lack of progress in ending the war in Ukraine. "Trump performed below market expectations," said analyst Artyom Nikolayev from Invest Era. "He gave 50 days during which the Russian leadership can come up with something and extend the negotiation track. Moreover, Trump likes to postpone and extend such deadlines." Against the Chinese yuan, the most traded foreign currency in Russia, the rouble strengthened 0.8% to 10.87 after weakening by over 1% on Friday. The Russian stock market rose 2.7% after Trump's statement, according to the Moscow Stock Exchange.
Bloomberg
33 minutes ago
- Bloomberg
CPI Shows Beginnings of Tariff Inflation: JPM's Kelly
David Kelly, chief global strategist at JPMorgan Asset Management, says the Federal Reserve has to 'stay on their guard' as he examines the US June CPI report. (Source: Bloomberg)
Yahoo
33 minutes ago
- Yahoo
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
